Navigation Links
Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
Date:4/30/2008

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that its Vice President of Research, Johannes Fruehauf, MD, Ph.D., is slated to speak at the RNAi World Congress meeting in Boston. His presentation, "Treatment of Gastrointestinal Targets using RNA Interference," is scheduled for 4:25 pm on Friday, May 2, at the Hilton Boston Logan Airport. Dr. Fruehauf is co-inventor of Cequent's proprietary TransKingdom RNA interference (tkRNAi(TM)) technology, designed to solve one of the key challenges to RNAi therapeutics -- delivery of the RNAi into the cell.

Cequent's goal with its first clinical candidate is to prevent polyp formation in patients with a high risk of developing colon cancer. In his talk, Dr. Fruehauf will give an overview of the company's preclinical-development program for the therapeutic, presenting efficacy data in mouse models and data on a major monkey toxicology study currently under way. The latter is the first study evaluating the safety and efficacy of tkRNAi in a non-human primate model -- an important step for Cequent in the development of tkRNAi-based drugs for human disease. In addition, Dr. Fruehauf will introduce Cequent's programs for inflammatory bowel disease (IBD) and human Papilloma virus (HPV), which targets cervical cancer.

Dr. Fruehauf's participation in the RNAi World Congress follows Cequent presentations at two other high-profile conferences. In March, Dr. Fruehauf introduced tkRNAi and its application in cancer prevention targeting beta-catenin at the Keystone Symposium on RNAi, MicroRNA, and Non-Coding RNA in Whistler, British Columbia. Cequent's Associate Director of RNAi Research, Jens Harborth, Ph.D., also presented at the conference, discussing the company's unique algorithm of developing tkRNAi target sequences, which are active across species. This approach allows the company to conduct accelerated toxicology and efficacy programs on the way to clinical trials. In April, Dr. Fruehauf presented mouse data from Cequent's colon cancer prevention program at the American Association for Cancer Research annual meeting in San Diego, California.

About tkRNAi(TM) -- TransKingdom RNA Interference

Cequent's tkRNAi technology offers an elegant "Trojan horse" solution to the problem of how to deliver the molecules triggering RNAi into the target cells and diseased tissues. In a proprietary process, we modify live, nonpathogenic E. coli bacteria to produce and deposit mediators of RNA interference (short hairpin RNA) directly into the target cells. The nonpathogenic bacteria are subsequently degraded by the host cells without adverse effects, and eliminated by the body through its own natural processes. This method has been shown to induce targeted gene silencing (in other words, it disables the "bad" gene or genes that cause disease, without affecting the surrounding genes), delivering significant therapeutic effects in multiple model systems, including live animals. All of the clinical drug candidates in our pipeline are based on this tkRNAi technology.

About Cequent Pharmaceuticals, Inc.

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases -- from inflammatory diseases to cancer -- based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi(TM)). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. For more information, visit http://www.cequentpharma.com.


'/>"/>
SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
Breaking Medicine News(10 mins):